FDA grants cancer drug regulatory short cut: Can draw on existing data

The first formal meeting with FDA yielded positive feedback to Oncology Venture. The Danish biotech company aims to obtain US approval of its breast cancer candidate and expects to file an application for initiating phase III trials during first half of 2019.

Photo: /ritzau/Lars Krabbe

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles